Combining azacytidine with CAOLD for treating relapsed T-cell lymphomas
Official title: Therapeutic Effect of Chemotherapy Azacytidine Plus CAOLD Regimen on Patients With Relapsed/Refractory Peripheral T-Cell Lymphomas
Run by Navy General Hospital, Beijing · NCT06176027 · Data updated 2026-11-12
This study is testing a new combination of azacytidine and CAOLD to see if it helps people with relapsed T-cell lymphomas feel better and live longer.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 52 (estimated) |
| Sponsor | Navy General Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | October 1, 2024 |
| Main results expected | September 1, 2028 |
| Study ends | September 1, 2030 |
| Registry record updated | October 29, 2024 |
| Trial ID | NCT06176027 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with pathologically confirmed angioimmunoblastic T-cell lymphoma who have relapsed or refractory disease after at least one line of systemic therapy.
✕Probably not a fit
Patients who do not have angioimmunoblastic T-cell lymphoma or those who have not undergone prior systemic therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter, prospective, single-arm phase II study aims to evaluate the safety and efficacy of azacytidine in combination with the CAOLD regimen for patients with relapsed or refractory peripheral T-cell lymphomas. The study will assess key outcomes such as response rate, progression-free survival (PFS), overall survival (OS), and toxicity associated with the treatment. Participants will receive the combined therapy and will be monitored closely for their response to the treatment and any adverse effects.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients with difficult-to-treat peripheral T-cell lymphomas.
How similar studies have gone: While there have been studies exploring treatments for peripheral T-cell lymphomas, the specific combination of azacytidine with the CAOLD regimen is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients must satisfy all following criteria to be enrolled in the study: * Pathologically confirmed angioimmunoblastic T-cell lymphoma according World Health Organization (WHO) classification; * Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF). * Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted; * Patient is willing and able to adhere to the study visit schedule and other protocol requirements; * Relapsed (after partial or complete response) or refractory AITL after at least one line of systemic therapy (there is no mandatory resting period after the previous treatment as long as the biochemistry and hematology labs meet the inclusion criteria as below.) * Meet the following lab criteria: * Absolute Neutrophil Count (ANC) ≥ 1,5 x 10\^9/L (≥ 1 x 10\^9/L if bone marrow (BM) involvement by lymphoma) * Platelet ≥ 75 x 10\^9/L (≥ 50 x 10\^9/L if BM involvement by lymphoma) * Hemoglobin ≥ 8 g/dL. * Anticipated life expectancy at least 3 months Exclusion Criteria: * Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment; * Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy; * Pregnant or lactating women
Where it's running
-
Navy General Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Liren Qian, PhD
- Email: qlr2007@126.com
- Phone: +861066957676
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Polatuzumab with zanubrutinib, rituximab, lenalidomide and prednisone as first-line treatment for diffuse large B-cell lymphoma
This trial tests whether adding polatuzumab, zanubrutinib, rituximab, lenalidomide, and prednisone is safe and effective as initial treatment for adults with untreated diffuse large B-cell lymphoma.
-
Using zanubrutinib and lenalidomide for maintenance in lymphoma patients
This study is testing whether the combination of zanubrutinib and lenalidomide can help people with diffuse large B-cell lymphoma stay in remission after chemotherapy.
-
Treatment for elderly patients with higher-risk myelodysplastic syndromes
This study is testing a new treatment combining two medications followed by a stem cell transplant to see if it helps older patients with higher-risk myelodysplastic syndromes live longer and have fewer complications.
-
Smart technology for patient-centered care in pulmonary embolism
A smartphone-based program using wearable tech and AI will help people with pulmonary embolism manage their health and see if it improves long-term outcomes.
-
Combining azacitidine with PD-1 therapy for treating relapsed Hodgkin lymphoma
This study is testing whether combining azacitidine with PD-1 therapy can help people with relapsed Hodgkin lymphoma feel better and live longer.
-
Monitoring blood markers in elderly patients with acute leukemia after chemotherapy
This study is testing if measuring certain blood markers can help doctors understand how well chemotherapy is working for older patients with acute leukemia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.